As a novel and advanced technology service provider, Creative Biolabs provides CellRapeutics™ receptor ligand-based CAR construction service. Our expert team has developed a variety of CAR products including scFv-based and non scFv-based CAR (receptor ligand-based), which can be tailored to meet your scientific goals and needs.
An diagram adapted from Shi et al., 2014.
Huan Shi, Meili Sun, Lin Liu and Zhehai Wang. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Molecular Cancer 2014, 13:219.
The classical CAR is composed of a single-chain variable fragment (scFv), a hinge region, a transmembrane domain (TM) and an endodomain (or two). Besides the classical CAR, Creative Biolabs also offers a novel non scFv-based CAR which can recognize and bind tumor antigens such as HER3 and HER4. This physiological CAR consists of an antigen receptor and a CD3ζ intracellular signaling domain with/without a TM and a spacer region, which can also be engineered into immune cells to target its ligands expressed on tumor cells. This approach increases the ability of T cells to recognize tumor associated targets and eliminate cancer cells, which has already been applied in the field of adoptive immunotherapy.
With years of experience, Creative Biolabs has created a solid platform for CAR construction. Please be free to contact us.
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved